Home›Rheumatology› Low preoperative AGR tied to worse survival in bladder cancer, meta-analysis finds
Low preoperative AGR tied to worse survival in bladder cancer, meta-analysis findsLow protein levels in blood may signal worse outcomes for bladder cancer
Frontiers in MedicinePublished August 25, 2026DOI ↗Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Consider preoperative AGR as a prognostic marker in bladder cancer, but validate its utility in prospective studies.
This meta-analysis pooled data from 8 studies involving 8305 patients with bladder cancer to evaluate the prognostic value of preoperative albumin-to-globulin ratio (AGR). The analysis focused on overall survival, progression-free survival, and recurrence-free survival, comparing low versus high AGR groups.
Low preoperative AGR was associated with worse cancer-specific survival (HR 1.25, 95% CI 1.11–1.38), progression-free survival (HR 1.92, 95% CI 1.35–2.50), and recurrence-free survival (HR 1.36, 95% CI 1.09–1.64). These pooled estimates indicate a consistent association between low AGR and poorer outcomes across the included studies.
The authors suggest that preoperative AGR could be integrated into clinical practice for risk assessment in bladder cancer. However, the analysis is limited by the lack of reported details on study heterogeneity, patient characteristics, and potential confounders. As a meta-analysis of observational studies, the findings represent associations, not causal relationships.
Clinicians should interpret these results cautiously. While AGR is a readily available biomarker, its independent prognostic value beyond established factors remains uncertain. Further prospective studies are needed to validate its clinical utility before routine use.
How this fits prior evidence
This meta-analysis extends prior coverage on prognostic biomarkers in bladder cancer by demonstrating that low preoperative AGR is associated with worse cancer-specific, progression-free, and recurrence-free survival. It complements earlier findings that elevated systemic immune-inflammation index (SII) is linked to reduced overall survival, suggesting that multiple inflammatory and nutritional markers may inform risk stratification. Unlike radiomics and spatial omics, which remain theoretical, AGR is a simple blood-based marker that could be more readily integrated into practice, though its clinical utility still requires validation.
When a person is diagnosed with bladder cancer, doctors look for every possible sign that helps them understand how the disease might progress. One simple marker they are looking at is the albumin-to-globulin ratio (AGR). This is a test that measures specific proteins in the blood to help gauge a patient's overall health and risk level.
A large review of data from over 8,000 patients found that a low AGR before surgery was linked to poorer outcomes. Specifically, patients with this lower ratio faced a higher risk of cancer progression and were less likely to remain free from the cancer returning after treatment.
While this test is not a new treatment, it serves as a reliable way for doctors to assess risk early on. Because the data shows a clear link between these protein levels and how the cancer behaves, doctors may use this measurement more often to help plan the best possible care for their patients.
What this means for you:
A low albumin-to-globulin ratio in blood tests can help doctors predict harder outcomes for bladder cancer patients.
Common questions
What does the albumin-to-globulin ratio mean for my diagnosis?
The albumin-to-globulin ratio (AGR) is a test that measures proteins in your blood. In this study of 8,305 patients, a low AGR was linked to worse outcomes, including a higher risk of cancer progression and lower rates of staying cancer-free after treatment.
How does this test help doctors treat bladder cancer?
The study suggests that the AGR is a reliable way for doctors to assess risk. By checking these protein levels before surgery, medical teams can better understand how the cancer might behave and use it as a tool to plan more informed care.
BackgroundThe preoperative albumin-to-globulin ratio (AGR) has emerged as a potential prognostic indicator in various malignancies. However, its specific prognostic value in bladder cancer remains to be fully elucidated. Thus, the association between preoperative the AGR and the prognosis of bladder cancer should be systematically evaluated through a meta-analysis of the available evidence.MethodsA systematic search was performed across major electronic databases (PubMed, Embase, and the Cochrane Library) to identify studies reporting the prognostic significance of AGR in bladder cancer. The primary outcomes were overall survival (OS) and progression-free survival (PFS). Hazard ratios (HRs) and 95% confidence intervals (CIs) were pooled to assess the strength of the association.ResultsA total of 8 studies involving 8305 patients were included in this meta-analysis. Our pooled results found that a low preoperative AGR was significantly associated with poor CSS (HR = 1.25, 95% CI: 1.11–1.38), PFS (HR = 1.92, 95% CI: 1.35–2.50), RFS (HR = 1.36, 95% CI: 1.09–1.64) compared with a high AGR in patients with bladder cancer.ConclusionThe preoperative AGR is a reliable prognostic factor for bladder cancer, suggesting that it could be integrated into clinical practice for risk assessment.
